The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Estimates of stage-specific preclinical sojourn time across 21 cancer types.
 
Michael S. Broder
Other Relationship - Abbvie (Inst); Akcea Therapeutics (Inst); Amgen (Inst); ASPC (Inst); AstraZeneca (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dompe US (Inst); Eisai (Inst); Ethicon (Inst); Genentech (Inst); GRAIL (Inst); Greenwich Biosciences (Inst); Helsinn Therapeutics (Inst); Illumina (Inst); Innovation and Value Initiative (Inst); Ionis Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Mirum Pharmaceuticals (Inst); Novartis (Inst); Otsuka (Inst); pathnostics (Inst); PhRMA Foundation (Inst); Prothena (Inst); Sage Therapeutics (Inst); Sanofi (Inst); Sunovion (Inst); Veana Therapeutics (Inst)
 
Sikander Ailawadhi
Honoraria - Amgen (Inst); Amgen (Inst); AstraZeneca (Inst); BMS (Inst); Janssen (Inst)
Consulting or Advisory Role - Beigene; Celgene; GlaxoSmithKline; Oncopeptides; Sanofi; Takeda
Research Funding - Amgen (Inst); BMS (Inst); Cellectar (Inst); Janssen Biotech (Inst); MedImmune (Inst); Pharmacyclics (Inst); Phosplatin Therapeutics (Inst); Xencor (Inst)
 
Himisha Beltran
Consulting or Advisory Role - Abbvie; Astellas Pharma; AstraZeneca; Blue Earth Diagnostics; Genzyme; GlaxoSmithKline; Janssen Oncology; Pfizer
Research Funding - Abbvie/Stemcentrx (Inst); Janssen (Inst); Lilly (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
L. Johnetta Blakely
Employment - Tennessee Oncology
Leadership - HCA Healthcare
Consulting or Advisory Role - GRAIL
Research Funding - Bristol-Myers Squibb
 
George Thomas Budd
Honoraria - Deciphera
Consulting or Advisory Role - Deciphera; Epic Sciences
Speakers' Bureau - Deciphera
Research Funding - Ambrx (Inst); Daiichi Sankyo/Lilly (Inst); Genentech/Roche (Inst); TRACON Pharma (Inst)
 
Laurie Carr
Honoraria - AstraZeneca; Blueprint Medicines; GRAIL; Takeda
Research Funding - Genentech; Ipsen; Merck
 
Michael Cecchini
Stock and Other Ownership Interests - Parthenon Therapeutics
Honoraria - Agios; AstraZeneca; Eisai
Travel, Accommodations, Expenses - Agios; AstraZeneca; Eisai; Genentech/Roche
 
Patrick Wayne Cobb
Stock and Other Ownership Interests - Abbott Laboratories; Abbvie; Amgen; Boston Scientific; crispr therapeutics; Intuitive Surgical; Johnson & Johnson; Medtronic; Merck; Pfizer (I); Siemens; Thermo Fisher Scientific; United Health Group
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Altor BioScience (Inst); Aptose Biosciences (Inst); AstraZeneca (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); Boston Biomedical (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Decibel Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Galera Therapeutics (Inst); Genentech/Roche (Inst); Incyte (Inst); Innocare (Inst); Ipsen (Inst); Isofol Medical (Inst); MEI Pharma (Inst); Merck (Inst); Mirati Therapeutics (Inst); Nektar (Inst); Novartis (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Pharmacyclics (Inst); Sanofi (Inst); Seagen (Inst); Spectrum Pharmaceuticals (Inst); Takeda (Inst); TG Therapeutics (Inst); United Therapeutics (Inst); Viracta Therapeutics (Inst)
 
Sarah N. Gibbs
Other Relationship - Abbvie (Inst); Akcea Therapeutics (Inst); Amgen (Inst); ASPC (Inst); AstraZeneca (Inst); Boston Scientific (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Dompé Farmaceutici (Inst); Eisai (Inst); Ethicon (Inst); Genentech (Inst); GRAIL (Inst); Greenwich Biosciences (Inst); Helsinn Therapeutics (Inst); Illumina (Inst); Innovation and Value Initiative (Inst); Ionis Pharmaceuticals (Inst); Jazz Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Mirum Pharmaceuticals (Inst); Novartis (Inst); Otsuka (Inst); pathnostics (Inst); PhRMA Foundation (Inst); Prothena (Inst); Sage Therapeutics (Inst); Sanofi (Inst); Sunovion (Inst); Veana Therapeutics (Inst)
 
Anuraag Kansal
Employment - GRAIL
Stock and Other Ownership Interests - GRAIL
Travel, Accommodations, Expenses - GRAIL
 
Ashley Kim
Employment - Allergan
Stock and Other Ownership Interests - Pfizer
 
Bradley J. Monk
Leadership - US Oncology
Honoraria - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoID; Clovis Oncology; Deciphera; Eisai; Elevar Therapeutics; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Iovance Biotherapeutics; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Starton Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Consulting or Advisory Role - Abbvie; Advaxis; Agenus; Akeso Biopharma; Amgen; Aravive; AstraZeneca; Asymmetric Therapeutics; Boston Biomedical; ChemoCare; Chemocare; ChemoID; Clovis Oncology; Deciphera; Eisai; Geistlich Pharma; Genmab/Seattle Genetics; GOG Foundation; Gradalis; ImmunoGen; Immunomedics; Incyte; Iovance Biotherapeutics; Karyopharm Therapeutics; Laekna Health Care; Merck; Mersana; Myriad Pharmaceuticals; Novocure; Nucana; Oncomed; Oncoquest; Oncosec; Perthera; Pfizer; Puma Biotechnology; Regeneron; Roche/Genentech; Senti Biosciences; Sorrento Therapeutics; Sorrento Therapeutics; Takeda; Tarveda Therapeutics; TESARO/GSK; Vascular Biogenics; Vavotar Life Sciences; Vigeo Therapeutics
Speakers' Bureau - AstraZeneca; Clovis Oncology; Eisai; Merck; Roche/Genentech; TESARO/GSK
Research Funding - Advaxis (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Genentech (Inst); Immunogen (Inst); Janssen (Inst); Lilly (Inst); Morphotek (Inst); Novartis (Inst); Nucana (Inst); Pfizer (Inst); Regeneron (Inst); Tesaro (Inst)
 
Lee S. Schwartzberg
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BeyondSpring Pharmaceuticals; Bristol-Myers Squibb; Genentech; Helsinn Therapeutics; Lilly; Myriad Genetics; Napo Pharmaceuticals; Odonate Therapeutics; Pfizer; Spectrum Pharmaceuticals
Speakers' Bureau - Coherus Biosciences; Merck; Puma Biotechnology; Seagen
Research Funding - Amgen (Inst); Pfizer (Inst)
 
Deborah J.L. Wong
Consulting or Advisory Role - Blueprint Medicines; Bristol-Myers Squibb; Genentech/Roche; Sanofi/Aventis
Research Funding - ARMO BioSciences (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Elevar Therapeutics (Inst); Enzychem Lifesciences (Inst); FSTAR (Inst); Genentech/Roche (Inst); Kura Oncology (Inst); Lilly; Merck Serono (Inst); Merck Sharp & Dohme (Inst); Pfizer (Inst); Regeneron (Inst)
 
Irina Yermilov
Employment - CAREMINDr
Leadership - CAREMINDr
Stock and Other Ownership Interests - CAREMINDr
Patents, Royalties, Other Intellectual Property - Dr. Yermilov has patents pending relating to her remote patient monitoring work at CAREMINDr.
Other Relationship - Abbvie; Akcea Therapeutics; Amgen; ASPC; AstraZeneca; Boston Scientific; Bristol-Myers Squibb; CAREMINDr; Celgene; Dompé Farmaceutici; Eisai; Ethicon; Genentech; GRAIL; Greenwich Biosciences; Helsinn Therapeutics; Illumina; Innovation and Value Initiative; Ionis Pharmaceuticals; Jazz Pharmaceuticals; Kite, a Gilead company; Mirum Pharmaceuticals; Novartis; Otsuka; pathnostics; PhRMA Foundation; Prothena; Sage Therapeutics; Sanofi; Sunovion; Veana Therapeutics